Artwork

Innehåll tillhandahållet av Labiotech. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Labiotech eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

How biotech is tackling myasthenia gravis

28:50
 
Dela
 

Manage episode 419977836 series 3361449
Innehåll tillhandahållet av Labiotech. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Labiotech eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles.

It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and men aged 50 and older.

To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.

01:07-04:26: Background on Dr Dana Vigier
04:26-07:07: What is myasthenia gravis?
07:07-09:43: What is the prognosis for someone diagnosed with myasthenia gravis?
09:43-11:33: How effective are current treatments for myasthenia gravis?
11:33-12:56: Do all the myasthenia gravis drugs work in the same way?
12:56-18:35: What R&D is taking place in myasthenia gravis?
18:35-21:14: Alexion and its work on myasthenia gravis
21:14-22:01: Myasthenia gravis clinical trials
22:01-23:58: The importance of myasthenia gravis awareness month
23:58-25:31: Would early diagnosis make a difference?
25:31-27:54: Transformation through new treatments
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Kapitel

1. How biotech is tackling myasthenia gravis (00:00:00)

2. Background on Dr Dana Vigier
 (00:01:07)

3. What is myasthenia gravis?
 (00:04:26)

4. What is the prognosis for someone diagnosed with myasthenia gravis?
 (00:07:07)

5. How effective are current treatments for myasthenia gravis?
 (00:09:43)

6. Do myasthenia gravis drugs work in the same way? 
 (00:11:33)

7. What R&D is taking place in myasthenia gravis?
 (00:12:56)

8. Alexion and its work on myasthenia gravis
 (00:18:35)

9. Myasthenia gravis clinical trials
 (00:21:14)

10. The importance of myasthenia gravis awareness month
 (00:22:01)

11. Would early diagnosis of myasthenia gravis make a difference? (00:23:58)

12. Transformation through new treatments (00:25:31)

114 episoder

Artwork
iconDela
 
Manage episode 419977836 series 3361449
Innehåll tillhandahållet av Labiotech. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Labiotech eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles.

It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and men aged 50 and older.

To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.

01:07-04:26: Background on Dr Dana Vigier
04:26-07:07: What is myasthenia gravis?
07:07-09:43: What is the prognosis for someone diagnosed with myasthenia gravis?
09:43-11:33: How effective are current treatments for myasthenia gravis?
11:33-12:56: Do all the myasthenia gravis drugs work in the same way?
12:56-18:35: What R&D is taking place in myasthenia gravis?
18:35-21:14: Alexion and its work on myasthenia gravis
21:14-22:01: Myasthenia gravis clinical trials
22:01-23:58: The importance of myasthenia gravis awareness month
23:58-25:31: Would early diagnosis make a difference?
25:31-27:54: Transformation through new treatments
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Kapitel

1. How biotech is tackling myasthenia gravis (00:00:00)

2. Background on Dr Dana Vigier
 (00:01:07)

3. What is myasthenia gravis?
 (00:04:26)

4. What is the prognosis for someone diagnosed with myasthenia gravis?
 (00:07:07)

5. How effective are current treatments for myasthenia gravis?
 (00:09:43)

6. Do myasthenia gravis drugs work in the same way? 
 (00:11:33)

7. What R&D is taking place in myasthenia gravis?
 (00:12:56)

8. Alexion and its work on myasthenia gravis
 (00:18:35)

9. Myasthenia gravis clinical trials
 (00:21:14)

10. The importance of myasthenia gravis awareness month
 (00:22:01)

11. Would early diagnosis of myasthenia gravis make a difference? (00:23:58)

12. Transformation through new treatments (00:25:31)

114 episoder

Tüm bölümler

×
 
Loading …

Välkommen till Player FM

Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.

 

Snabbguide